Freshfields advises Roivant in sale of Dermavant to Organon

Freshfields advised Roivant Sciences Ltd. in the sale of Dermavant Sciences Ltd. to Organon & Co. Dermavant is a Roivant subsidiary dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Organon agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion. 

More information about the transaction can be found here.

The Freshfields team included corporate/M&A partners Damien Zoubek, Jenny Hochenberg and Tomas Rua, corporate/M&A associate Annie Powderly and life sciences counsel Jeff Jay.

Associates Nana Kessie, Nicole Johnson, Wicy Wang and Patrick Boldea also advised on corporate/M&A matters; associates Jake Silvers, Shannon O’Hara and Dylan O’Connor also advised on life sciences matters; partner Lori Goodman, senior associate Andrew Herman and associate Lina Zhu advised on employee compensation and benefits matters; partner Steven Matays, senior associate Brendan Counihan and associates Hannah Golden and Dominik Luczak advised on tax matters; partners Meghan Rissmiller and Rod Carlton, special counsel Charles Ramsey, senior associates Vadim Egoul and Alessandra Galea and associate Emily Strickland advised on antitrust and competition matters; partners Christine Lyon and Brock Dahl and associate Christine Chong advised on data privacy and security matters and partner Stephanie Brown-Cripps and associate Maylin Meisenheimer advised on sanctions matters.